NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)

CompletedN/A

Sponsor: Sanofi

Conditions: Immune-mediated Thrombocytopenic Purpura

Interventions: Caplacizumab

Countries: France

The purpose of this multi-country, retrospective data collection study (chart review) is to describe the effectiveness and safety of caplacizumab in pediatric patients with iTTP.

Eligibility overview

Sex: ALL

Age: — to 18 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patient's aged ≤18 years at start of caplacizumab treatment initiation
* Patient has a diagnosis of iTTP documented in the medical records
* Patient was treated with caplacizumab within the eligibility period

Exclusion Criteria:

* Patient declined use of data for study (where local regulations require patient notification of planned study)
* Patient's medical chart is missing or not retrievable

Locations (1)

Chilly-Mazarin, France